What Are Prostaglandin Analogues in Lash Serum?
Plain answer: Prostaglandin analogues are chemicals that copy some jobs of natural prostaglandins. Some are eye drugs. Some are put in lash serums. Controlled human evidence supports LATISSE 0.03% when used as labeled. That evidence does not cover every related chemical. Safety findings and rules can change with each name and country.
Review status: This is a source-checked editorial draft. Qualified review required before indexation. An ophthalmologist or optometrist must review ocular and drug claims. A dermatologist or cosmetic toxicology expert must review claims within their scope.
Quick facts
| Ingredient class | Compounds with prostaglandin-like biological activity. The class includes approved drugs and cosmetic ingredients. |
|---|---|
| Best-supported eyelash use | Prescription bimatoprost 0.03% for eyelash hypotrichosis. |
| Evidence grade | Bimatoprost: A. A class-wide claim for cosmetic analogues: E unless the exact compound has direct human eyelash evidence. |
| Main safety sources | Current drug labels, Health Canada, and the European Commission Scientific Committee on Consumer Safety (SCCS). |
| Source check | 2026-07-11 |
Which names belong to this ingredient family?
Do not rely on a simple word fragment such as prost. A fragment can miss a covered name or flag an unrelated one. Use a dated list tied to an authority or to a current product label.
| Name | What the source establishes | Important limit |
|---|---|---|
| Bimatoprost | The current LATISSE label identifies it as a prescription prostaglandin analogue for eyelash hypotrichosis. | Its efficacy and adverse-reaction rates do not transfer automatically to another analogue. |
| Isopropyl Cloprostenate | The 2026 SCCS opinion assessed it for cosmetic lash and brow growth use. Health Canada's prohibited list names it within the prostaglandin family. | An SCCS scientific opinion is not itself an EU ban. |
| 15-keto Fluprostenol Isopropyl Ester | One 2019 double-blind, vehicle-controlled study tested an 80 microgram per milliliter gel in 40 participants and reported greater eyelash length with the active gel. | This supports the exact preparation, not the whole ingredient class. One person in the active group reported eye heaviness and headache. |
| Methylamido-Dihydro-Noralfaprostal (MDN) | The 2026 SCCS opinion assessed this exact compound. | Do not infer which products currently use it without a dated official formula. |
| Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) | The 2026 SCCS opinion assessed this exact compound. | Do not replace the full INCI name with an unverified alias. |
Do prostaglandin analogues grow eyelashes?
There is no honest class-wide answer. The current LATISSE label supports bimatoprost for increasing eyelash length, thickness, and darkness. That is evidence for the exact drug, strength, route, and indication. It is not proof that every cosmetic analogue or every serum formula produces the same result.
A 2024 peer-reviewed review found substantial efficacy evidence for bimatoprost. It described non-bimatoprost prostaglandin ingredients as potentially beneficial but called for more research on their safety profiles. Product testimonials and brand consumer surveys remain formula-level marketing evidence, not ingredient-specific controlled trials.
Effectiveness evidence
The Lash List editorial grade key: A = strong controlled human evidence for the exact use. B = one controlled human study. C = a small uncontrolled human formula study. D = laboratory, animal, scalp-hair, or supplier evidence. E = label presence, theory, or no direct human eyelash evidence. This is our editorial rubric, not a recognized clinical grading system. Grades do not rate safety.
| Claim | Evidence grade | Allowed conclusion |
|---|---|---|
| Bimatoprost 0.03% used as labeled for eyelash hypotrichosis | A | The prescription drug is approved for increasing eyelash growth, including length, thickness, and darkness. |
| 15-keto fluprostenol isopropyl ester 80 micrograms per milliliter in the 2019 controlled study | B | One small controlled study supports the exact gel. It does not prove that other analogues or formulas work the same way. |
| All prostaglandin analogues work like bimatoprost | E | Not established. Similar class or mechanism does not prove equal clinical results. |
| A named cosmetic serum works because it lists an analogue | E unless the exact formula was studied | An ingredient list establishes presence only. It does not establish dose, effect size, or causation. |
Safety assessment
| Assessment status | Mixed by exact compound. Bimatoprost is assessed under prescription-label conditions. SCCS said IPCP, MDN, and DDDE could not be considered safe for cosmetic lash and brow growth use. |
|---|---|
| Authority | U.S. DailyMed drug label; SCCS final opinion SCCS/1680/25; Health Canada Cosmetic Ingredient Hotlist. |
| Scope | Exact compounds, stated uses, concentrations where supplied, and named jurisdictions. This is not a global class ruling. |
| Jurisdiction | United States prescription label; European Union scientific opinion; Canadian cosmetic prohibition framework. |
| Known effects | The bimatoprost label lists eye itching, conjunctival redness, skin pigmentation, iris pigmentation, and other warnings. Those incidence figures must not be copied onto cosmetic analogues. |
| Data gaps | Exact cosmetic concentrations, long-term eye-area exposure, reproductive and developmental data for assessed cosmetic analogues, and current finished-formula data. |
| Checked date | 2026-07-11 |
What do regulators say?
United States: The FDA explains that cosmetics generally do not receive premarket approval, except color additives. A cosmetic claim that treats or changes body structure can bring drug rules into play. This is different from FDA approval of LATISSE as a prescription drug.
Canada: Health Canada's Hotlist places prostaglandins, their salts, derivatives, and analogues on the prohibited cosmetic list. The current list names examples including bimatoprost and isopropyl cloprostenate.
European Union: In February 2026, SCCS published a final scientific opinion. It said IPCP, MDN, and DDDE could not be considered safe for cosmetic products intended to promote eyelash or eyebrow growth. This is an expert safety opinion. It should not be rewritten as a regulation or automatic EU ban.
How should you read a product label?
- Copy the full ingredient list from the current box or official product page.
- Keep exact spelling. Do not shorten a long INCI name before checking it.
- Use the Ingredient Checker as a bounded name screen, not a medical clearance.
- Recheck the brand label because formulas can change by date and country.
- Ask an eye clinician before use if you use glaucoma medicine or have an eye condition.
Sources and evidence limits
- SCCS final opinion SCCS/1680/25, checked 2026-07-11.
- Health Canada Hotlist guidance and the prohibited ingredient list, checked 2026-07-11.
- Current LATISSE label on DailyMed, revised July 2024.
- 2019 controlled study of 15-keto fluprostenol isopropyl ester gel. This supports only the tested preparation and study conditions.
- 2024 comprehensive review of eyelash serums. This is a review, not a regulator decision.
Product label examples
These examples connect exact names to products, not one ingredient to a promised result. The current LATISSE drug label names bimatoprost, and Grande Cosmetics' official U.S. ingredient list names isopropyl cloprostenate. Sources checked July 11, 2026; formulas can change.
Related ingredient pages
Use the evidence system
Return to the lash serum ingredient hub, paste a current ingredient label into the checker, or read the ingredient risk guide.
This page is educational. It does not diagnose an eye condition or replace advice from a qualified clinician.